Voxzogo subcutaneous injection 1.2 mg

Voxzogo subcutaneous injection 1.2 mg, manufactured by BioMarin Pharmaceutical Japan, contains vosoritide (genetical recombination). Vosoritide is an analog of C-type natriuretic peptide (CNP) indicated to promote linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses. It is supplied as a 1.2mg/1 bottle (with dissolving solution) injectable drug (YJ code: 3999465D3020).